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A B S T R A C T
Background
There is conflicting information about the impact of the menopause on glycaemic control amongst women with type 1 diabetes. Some
menopausal women with type 1 diabetes are treated with hormone replacement therapy (HRT) but the effects of this treatment have, to
date, not been established.
Objectives
To assess the effects of HRT for women with type 1 diabetes mellitus.
Search methods
We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL and PsycINFO from their inception to June 2012. The last search was run
for all databases on 18 June 2012.
Selection criteria
We selected randomised controlled trials or controlled clinical trials that involved peri- or postmenopausal women with type 1 diabetes
undergoing HRT as an intervention.
Data collection and analysis
Two researchers independently applied the inclusion criteria to the identified studies and assessed risk of bias. Disagreements were re-
solved by discussion or by intervention by a third party. Descriptive analysis was conducted for the review.
Main results
Ninety-two publications were screened. No studies met the inclusion criteria exclusively but one study that included both type 1 and type
2 diabetes participants was considered. This randomised clinical trial (RCT) compared HRT (N = 27) with placebo (N = 29) over 12 months.
The outcome measures were cardiovascular risk factors, including lipid profile, glycaemic control, blood pressure and body weight. No
significant differences between placebo and HTR were detected. Patient-important outcomes like all-cause mortality, cardiovascular dis-
ease, diabetic complications or health-related quality of life were not investigated.
Authors' conclusions
There is a lack of evidence around the use of HRT in women with type 1 diabetes. The one study that has been undertaken in this area is
underpowered. More RCTs are required in the area to examine the impact of HRT on glycaemic control and cardiovascular outcomes.
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P L A I N   L A N G U A G E   S U M M A R Y
Hormone replacement therapy for women with type 1 diabetes mellitus
There are increasing numbers of people living with type 1 diabetes mellitus. The main aim of treatment for diabetes is to maintain good
quality of life and to minimise, or prevent, the development of diabetic complications by controlling blood glucose levels. Women with
type 1 diabetes frequently express difficulties in controlling their blood glucose levels during the menopausal phase of their lives. However,
the cause of this has not been explored.
Hormone replacement therapy is a treatment that is prescribed to many women to alleviate the symptoms associated with the
menopause.
The literature surrounding hormone replacement therapy and type 1 diabetes has never been systematically searched and reviewed.
The evidence available for healthcare professionals to call upon relating to the management of menopausal women with type 1 diabetes
is vague. There is conflicting literature regarding the use of hormone replacement therapy in women with type 1 diabetes, as many of
the studies also included women with type 2 diabetes. We found one study with a type 1 diabetes subgroup involving 56 participants
receiving either hormone replacement therapy or placebo over 12 months. No statistically significant differences were found between
hormone replacement therapy and placebo. Patient-important outcomes like death from any cause, cardiovascular disease (for example,
heart attack, stroke), diabetic complications (for example, diabetic eye disease, diabetic kidney disease) or health-related quality of life
were not investigated.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
Hormone replacement therapy compared with placebo for women with type 1 diabetes mellitus
Patient or population: peri- or postmenopausal women with type 1 diabetes mellitus
Settings: outpatients
Intervention: hormone replacement therapy ((oestrogen (17B-oestradiol, 2 mg) and progesterone (norethisterone acetate, 1 mg))
Comparison: placebo
Outcomes No of Partic-
ipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Diabetes and non-diabetes re-
lated morbidity
See com-
ment
See comment Not investigated
Death from any cause See com-
ment
See comment Not investigated
Adverse effects
[follow-up: 12 months]
56
(1)
⊕⊝⊝⊝
very lowa
Most frequently reported event was breast pain (37 type 1 dia-
betes mellitus and type 2 diabetes mellitus participants on hor-
mone replacement therapy (HRT) versus nine placebo partici-
pants); vaginal bleeding occurred in 26 HRT versus three place-
bo participants.
Health-related quality of life See com-
ment
See comment Not investigated
Glycaemic control (fruc-
tosamine levels)
[follow-up: 12 months]
56
(1)
⊕⊝⊝⊝
very lowa
No statistically significant differences between intervention
and comparator groups
Economic data See com-
ment
See comment Not investigated
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
aDue to very serious indirectness, serious risk of bias, low number of participants and studies
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B A C K G R O U N D
Description of the condition
Diabetes mellitus is a metabolic disorder resulting from a defect in
insulin secretion, insulin action, or both. A consequence of this is
chronic hyperglycaemia (that is elevated levels of plasma glucose)
with disturbances of carbohydrate, fat and protein metabolism.
Long-term complications of diabetes mellitus include retinopathy,
nephropathy and neuropathy. The risk of cardiovascular disease
and cancer is increased.
It is acknowledged that there is an increasing number of people
who suffer from type 1 diabetes (Diabetes UK 2006). The main aims
of treatment for type 1 diabetes are to maintain good health-relat-
ed quality of life and to minimise, or prevent, the microvascular and
macrovascular complications caused by the disease through good
glycaemic control (Norris 2001; Signuroardottir 2005). A major trial
has demonstrated conclusively that optimal glycaemic control can
improve the physical and psychological well-being of people with
type 1 diabetes (DCCT 1993). Physiological changes like pregnancy,
weight gain, puberty and psychological issues like stress are known
to affect glycaemic control (Russel 2001; Weinger 2001). It is well
recognised that changes in sex hormones can increase insulin resis-
tance during puberty and pregnancy (Dahlgren 2006). These find-
ings imply that during the menopause a woman's requirement for
insulin will be altered.
The menopause is a stage in the female reproductive cycle that oc-
curs as the ovaries stop producing oestrogen causing the repro-
ductive system to cease functioning (Freeman 2007). As the body
adapts to changing levels of natural hormones various symptoms
may be experienced. These include amongst others: (1) hot flush-
es, palpitations, night sweats, (2) mood swings, lack of concentra-
tion, (3) vaginal dryness, decreased libido, (4) weight changes. To
overcome some of these symptoms hormone replacement thera-
py (HRT) can be prescribed. There is emerging evidence about the
benefits and disadvantages of HRT in women with type 1 diabetes
(Andersson 2000; Smith 2000). Insulin resistance can be modified
by HRT but to date much of the evidence relating to HRT in dia-
betes has been extrapolated from non-diabetic women. There is
some evidence that women with diabetes have a blunted response
to the beneficial effects of HRT on lipids (Robinson 1996). Women
with diabetes are at increased risk of cardiovascular disease with
the pathogenesis linked to insulin resistance (Satter 1996). Interest-
ingly, HRT has been found to be prescribed less in women with dia-
betes than in women without diabetes (Progetto Menopausa Italia
Study Group 2001). However, no link has been found between the
use of HRT and mortality in a longitudinal study of women with di-
abetes in the US (Klein 1999), while there is a suggestion that gly-
cosylated haemoglobin may be significantly decreased in women
with type 2 diabetes who take postmenopausal oestrogen (Brus-
saard 1992).
The experience and management of the menopause amongst
women is unique and at times complex. It is proposed that for
women with type 1 diabetes managing the menopause is more
complex due to changes in their physical and psychological sta-
tus impacting on their glycaemic control. These women usually
have an earlier onset of menopause than women without diabetes
(Zarzycki 2005). From practice it is known that often women con-
fuse the signs of the menopause with hypoglycaemia. Both of these
physiological changes can result in night sweats, mood changes
and palpitations; therefore, it is difficult for the women to distin-
guish whether they are suffering from hypoglycaemia or experi-
encing menopausal symptoms. Interestingly, clinical experience
suggests that menopausal women are sometimes inappropriately
treating their perceived hypoglycaemic symptoms resulting in hy-
perglycaemia.
Additionally, some people are administering HRT to alleviate symp-
toms of the menopause but the effectiveness of this intervention
has not been clearly established. In addition to the signs and symp-
toms of the menopause being confused by women with the symp-
toms of hypoglycaemia causing possible inappropriate insulin use,
alterations in diet, weight and mood sometimes experienced dur-
ing the menopause can also necessitate changes in insulin use.
Overall, this can necessitate women to alter their self-management
regimen significantly which can cause further physical and psycho-
logical stress.
The evidence available to patients and healthcare professionals
surrounding the management of menopausal women with type 1
diabetes and health-related quality of life issues is vague. There is
conflicting literature surrounding the use of HRT in women with
type 1 diabetes and this literature has never been systematically
searched, retrieved and reviewed.
Description of the intervention
The intervention under investigation is HRT versus no hormone
therapy in women with type 1 diabetes.
For many years, oestrogen alone or in combination with progesto-
gens, otherwise known as HRT, has been the treatment of choice
for control of problematic menopausal symptoms and for the pre-
vention of osteoporosis. A recent publication from the Internation-
al Menopause Society 2008 has stated that HRT remains the first-
line and most effective treatment for menopausal symptoms. The
use of HRT in all women has declined after the publication of sev-
eral studies which linked the treatment to increased risk of breast
cancer (Beral 2003; Women's Health Initiative Investigators 2002),
coronary heart disease (Women's Health Initiative Investigators
2002) and venous thromboembolism (Hulley 2002).
HRT should currently only be prescribed for menopausal symptoms
and not for prevention of osteoporosis or cardiovascular disease. It
is currently recommended that the lowest dose of HRT based on re-
lieving menopausal symptoms should be prescribed (Khoo 2005).
Oral HRT regimens are well tolerated and are considered as first-
line therapy in most women. There is significant individual varia-
tion in response to HRT and it is often appropriate to try two or three
different preparations. Women should be encouraged to persevere
with a new preparation for two to three months as any side-effects
experienced initially may settle with time. Women should be re-
viewed three months after commencing therapy. The ongoing need
for HRT should be reassessed at least annually. Blood pressure
should be checked 6 to 12 monthly, and each woman encouraged
to attend cervical and breast screening programmes. Breast aware-
ness should be encouraged. Stopping HRT abruptly can cause some
women to have hot flushes and it should, therefore, be withdrawn
gradually by decreasing dosages over three to six months.
HRT is contra-indicated in the presence of active venous throm-
boembolism, unexplained vaginal bleeding, oestrogen dependent
tumours (breast and endometrial cancer), current or recent cardio-
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vascular disease and acute porphyria. Women who have not had
a hysterectomy should be commenced on a sequential or continu-
ous combined form of HRT starting at the lowest dose available and
increasing if required to give symptom control. Continuous com-
bined therapy (period-free HRT) should only be used by women
who are at least a year past the menopause or over 54 years of
age. Both oestrogen and progestogen are taken daily to give a peri-
od-free regimen. Erratic bleeding is common in the first few months
of use. For women who have had a hysterectomy unopposed oe-
strogens should be prescribed.
Possible and known adverse e8ects of the intervention
Glycaemic control
Studies have indicated that HRT appears to lower glycaemic con-
trol as indicated by glycosylated haemoglobin A1c (HbA1c) in
women who have type 2 diabetes. HRT users have a lower than
average HbA1c than non-HRT users (Ferrara 2001). Furthermore,
current HRT users may experience better glycaemic control than
those who have never used it or who had previously done so (Cre-
spo 2002). Both these studies indicate that glycaemic control is af-
fected and can be improved in women who have type 2 diabetes
taking HRT.
To our knowledge the relationship between HRT and glycaemic
control has not been investigated in type 1 diabetes.
Changes in insulin sensitivity
Studies involving women with type 2 diabetes indicate that oestra-
diol given orally or transdermally tends to improve insulin sensitiv-
ity (Cagnacci 1992). However, it has also been shown that a dose of
1.25 mg/day reduces insulin sensitivity (Ajabor 1972).
Combining HRT with progestogen may reduce insulin sensitivity
(Lindheim 1993). Furthemore, high doses of approximately 20 mg
have no effect on insulin sensitivity, with lower doses of 10 mg/day
leading to a decrease in insulin concentrations (Crook 1997).
To our knowledge the relationship between HRT and changes in in-
sulin sensitivity has not been investigated in type 1 diabetes.
Health-related quality of life
The provision of information, education and psychological support
to facilitate self management are essential components of diabetes
care and are known to improve health-related quality of life. The in-
terpretation of the data on the effect of HRT on health-related qual-
ity of life varies, with the WISDOM study showing measurable im-
provements in health-related quality of life, sexuality and joint pain
in symptomatic women (Welton 2008); however, women with dia-
betes were not investigated separately. HRT has been found to be
efficacious in comparison with placebo in reducing the frequency
and severity of hot flushes in healthy menopausal women (MacLen-
nan 2004).
Coronary heart disease (CHD)
The Women's Health Initiative study (Women's Health Initiative In-
vestigators 2002) showed an increase in CHD events from 30 to 37
cases per 10,000 treated women. However, more recent studies
have suggested that HRT does not cause an increase in CHD risk
and may have a cardioprotective role in younger women in the ear-
ly postmenopausal years (Rossouw 2007). Whether this is the case
in women with type 1 diabetes is unclear.
Venous thromboembolism (VTE)
While the risk of VTE with HRT remains low, a two-fold increase in
VTE has been found when standard doses of oral HRT are compared
to placebo (Cushman 2004). Healthy postmenopausal women are
at low risk of VTE but the use of HRT is best avoided in women with
a previous history of VTE.
Ovarian cancer
While the Million Women Study collaborators found an increased
risk of ovarian cancer in women using HRT compared to women
who had never used HRT, the risks were 'small' (one extra case of
cancer in 2500 users of HRT) with the risk falling back to pre-use
levels when the HRT was discontinued (Million Women Study Col-
laborators 2007).
Breast cancer
The effects of HRT on breast cancer appear to be related to the type
of HRT and the duration of the therapy with combined oestrogen
and progesterone therapy taken over five years demonstrating the
greatest risk. The Women's Health Initiative showed an increase in
breast cancer of eight cases per 10,000 treated women (Women's
Health Initiative Investigators 2002).
Reduced bone mineral density
HRT has a beneficial effect on bone mineral density with the large
studies (Women's Health Initiative Investigators 2002) showing HRT
was effective in preventing fractures secondary to osteoporosis.
Why it is important to do this review
There is currently some ambiguity surrounding the use of HRT in
women with type 1 diabetes . The current literature offers conflict-
ing information making clinical decisions problematic. There have
been no systematic reviews of the evidence for methods relating
to the impact of HRT on menopausal women with type 1 diabetes
undertaken to date. This information is necessary to guide profes-
sionals when they are considering how best to empower women to
manage their diabetes during this stage in their life and also to in-
form future studies on this group.
O B J E C T I V E S
To assess the effects of hormone replacement therapy for women
with type 1 diabetes mellitus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and controlled clinical trials
(CCTs).
Types of participants
Peri- and postmenopausal women with type 1 diabetes.
Types of interventions
Intervention• Hormone replacement therapy for women with type 1 diabetes
mellitus.
Hormone replacement therapy for women with type 1 diabetes mellitus (Review)
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Control• Placebo.• No intervention.• Usual care.
Types of outcome measures
Primary outcomes• Glycaemic control (glycosylated haemoglobin A1c (HbA1c),
blood glucose levels (self monitored)).• Diabetes and non-diabetes related morbidities.• Health-related quality of life (using validated instruments).
Secondary outcomes• Total daily insulin dosage.• Body mass index (BMI), weight.• Frequency and severity of hypoglycaemia.• Death from any cause.• Adverse effects.• Economic data.
Covariates, e8ect modifiers and confounders• Duration of diabetes.• Compliance with treatment.• Diabetes management skills.• Presence of diabetes complications.• Age.• Level of physical activity.
Timing of outcome measurement
Short term (less than six months)• Glycaemic control.• Total daily insulin dose.• Diabetes and non-diabetes related morbidities.• Averse effects.
Medium term (six to 12 months)• Diabetes and non-diabetes related morbidities.• Health-related quality of life.• Adverse effects.• BMI, weight or both.
Long term (more than 12 months)• Diabetes and non-diabetes related morbidities.• Adverse effects.• Death from any cause.• Economic data.
Search methods for identification of studies
Electronic searches
We used the following sources from inception until specified date
for the identification of trials.
• The Cochrane Library (issue 3, 2012).• MEDLINE (until June 2012).• EMBASE (until June 2012).• CINAHL (until June 2012).• PsycINFO (until June 2012).
For detailed search strategies please see under Appendix 1.
The ISI Web of Knowledge database was searched for relevant ab-
stracts from conference proceedings. We also searched databases
of ongoing trials: 'Current Controlled Trials' (www.controlled-trial-
s.com - with links to other databases of ongoing trials).
Additional key words of relevance could have been detected during
any of the electronic or other searches. In this case, we would have
modified electronic search strategies to incorporate these terms.
We planned to include studies published in any language.
Searching other resources
We tried to identify additional studies by searching the reference
lists of included trials and systematic reviews, meta-analyses and
health technology assessment reports. Potential missing and un-
published studies were sought by contacting expert authors in the
field.
Data collection and analysis
Selection of studies
To determine the studies to be assessed further, two review authors
(LK, JC) independently reviewed the abstracts, title or both sec-
tions of every record retrieved. All potentially relevant articles were
investigated as full text. Only one study was identified as being suit-
able for inclusion. An adapted PRISMA (preferred reporting items
for systematic reviews and meta-analyses) flow-chart (see Figure 1)
of study selection is attached (Liberati 2009).
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Figure 1.   Study flow diagram.
 
Data extraction and management
Two review authors (LK, JC) independently abstracted relevant
population and intervention characteristics using standard data
extraction templates (for details see 'Characteristics of included
studies'; Table 1; Appendix 2; Appendix 3; Appendix 4; Appendix 5;
Appendix 6) with any disagreements to be resolved by discussion,
or if required, by a third party. We sought any relevant missing in-
formation on the trial from the original author(s) of the article, if
required.
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Assessment of risk of bias in included studies
Two authors (LK, JC) assessed the one trial independently.
We assessed risk of bias using The Cochrane Collaboration’s tool
(Higgins 2011). We used the following criteria.
• Was the allocation sequence adequately generated?• Was the allocation adequately concealed?• Was knowledge of the allocated intervention adequately pre-
vented during the study?• Were incomplete outcome data adequately addressed?• Were reports of the study free of suggestion of selective outcome
reporting?• Was the study apparently free of other problems that could put
it at a high risk of bias?
A judgement of ‘Yes’ indicates low risk of bias, ‘No’ indicates high
risk of bias and ‘Unclear’ indicates unclear or unknown risk of bias.
We used these criteria for a judgement of ‘Yes’, ‘No’ and ‘Unclear’
for individual bias items as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
We planned to assess the impact of individual bias domains on
study results at endpoint and study levels.
Measures of treatment e8ect
We planned to express dichotomous data as odds ratios (ORs) or
risk ratios (RRs) with 95% confidence intervals (CIs). We planned to
express continuous data as mean differences (MD) with 95% CI.
Unit of analysis issues
We planned to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome.
Dealing with missing data
We wanted to obtain relevant missing data from authors, if feasi-
ble, and planned to perform evaluation of important numerical da-
ta such as screened, randomised patients, as well as intention-to-
treat (ITT) and per protocol (PP) populations. We planned to inves-
tigate attrition rates, for example, drop-outs, losses to follow-up,
withdrawals. We also wanted to critically appraise issues of miss-
ing data and techniques to handle these (for example, last-obser-
vation-carried-forward (LOCF)).
Assessment of heterogeneity
In the event of substantial clinical or methodological or statistical
heterogeneity we planned not to report study results as meta-an-
alytically pooled effect estimates. We planned to identify hetero-
geneity by visual inspection of forest plots, by using a standard Chi2
test and a significance level of α = 0.1, in view of the low power of
this test. We wanted to specifically examine heterogeneity with the
I2 statistic quantifying inconsistency across studies to assess the
impact of heterogeneity on the meta-analysis (Higgins 2002), where
I2 values of 50% and more indicates a considerable level of incon-
sistency (Higgins 2003).
When heterogeneity was found, we planned to determine potential
reasons for it by examining individual study and subgroup charac-
teristics.
Assessment of reporting biases
We planned to use funnel plots to assess for the potential existence
of small study bias. There are a number of explanations for the
asymmetry of a funnel plot (Sterne 2011). Therefore, we planned to
carefully interpret results (Lau 2006).
Data synthesis
We planned to summarise data statistically if they were available,
sufficiently similar and of sufficient quality. We would have per-
formed statistical analyses according to the statistical guidelines
referenced in the most recent version of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses and want-
ed to investigate interaction.
• Post- and perimenopause.• Type of HRT (oestrogen only, combined oestrogen and proges-
terone).
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on effect sizes.
• Restricting the analysis to published studies.• Restricting the analysis taking into account risk of bias, as spec-
ified above.• Restricting the analysis to very long or large studies to establish
how much they dominate the results.• Restricting the analysis to studies using the following filters: di-
agnostic criteria, language of publication, source of funding (in-
dustry versus other), country.
We also planned to test the robustness of the results by repeating
the analysis using different measures of effect size (RR, OR etc.) and
different statistical models (fixed-effect and random-effects mod-
els).
R E S U L T S
Description of studies
For a detailed description of studies, see Tables 'Characteristics of
included studies' and 'Characteristics of excluded studies'.
Results of the search
The initial search identified 92 records. After removal of duplicates
and review of the 87 titles and available abstracts, four potential
full text articles and theses were identified for further assessment.
Only one study met the inclusion criteria of the review. We excluded
the other studies on the basis of their titles or abstracts because
they did not meet the inclusion criteria or were not relevant to the
question under study or were a duplicate report (see Figure 1 for the
amended PRISMA (preferred reporting items for systematic reviews
and meta-analyses) flow chart).
Included studies
The details of the included study (Scott 2004) are described in the
'Characteristics of included studies' table and appendices. This
Hormone replacement therapy for women with type 1 diabetes mellitus (Review)
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was a randomised controlled study, although the randomisation
process was not stated. Study duration was 12 months.
Participants and setting
The included study involved postmenopausal women who had
type 1 or type 2 diabetes. Stratification was conducted based on
the type of diabetes. Both the type 1 (T1DM) and type 2 diabetes
(T2DM) groups consisted of a hormone replacement intervention
(HRT) and comparator (placebo) arm. After an initial six week run-
in period, participants were randomly allocated to HRT or placebo.
Mean age for the HRT group was 60 years and for the placebo group
was 59 years. Of the original total (including T1DM and T2DM) of 150
women, 55 withdrew throughout the study, with the main reasons
being due to adverse effects or persistence of menopausal symp-
toms. Data describing the percentage of drop-out relating to type
of diabetes were not provided. The included trial's baseline charac-
teristics are stated in Appendix 3.
Interventions
The intervention group received HRT (oestrogen (17B-oestradiol)
and progestogen (norethisterone acetate, 1 mg)), while the place-
bo controlled group did not (placebo not described). The descrip-
tion of the intervention for the included trial's is shown in Appendix
2.
Outcomes
The details of the outcomes are stated in the 'Characteristics of in-
cluded studies' and Appendix 4.
Excluded studies
There were three studies excluded from the review. The reasons for
exclusion were due to non-type 1 diabetes participants, non-HRT
intervention used, or participants were not menopausal (see 'Char-
acteristics of excluded studies').
Risk of bias in included studies
For details on the methodological quality of the included study see
'Characteristics of included studies'.
E8ects of interventions
See: Summary of findings for the main comparison
Baseline characteristics
For details of baseline characteristics, see Appendix 3.
Primary outcomes
No interaction between type of diabetes (T1DM or T2DM) and treat-
ment (HRT or placebo) achieved statistical significance for any of
the variables analysed. Study authors pooled all results by combin-
ing all diabetes participants.
Diabetes and non-diabetes related morbidities and health-related
quality of life were not investigated.
Glycaemic control
Glycaemic control (measuring fructosamine) showed no statistical-
ly significant treatment effect (P = 0.27) or effect of type of diabetes
(P = 0.45).
Secondary outcomes
No interaction between type of diabetes (T1DM or T2DM) and treat-
ment (HRT or placebo) achieved statistical significance for any of
the variables analysed. Study authors pooled all results by combin-
ing all diabetes participants.
Death from any cause, frequency and severity of hypoglycaemia,
body mass index, weight, total daily insulin dosage and economic
data were not investigated.
Adverse e(ects
HRT was associated with more adverse events: the most frequent-
ly reported event was breast pain (37 HRT T1DM and T2DM partici-
pants versus nine placebo participants); vaginal bleeding occurred
in 26 HRT versus three placebo participants.
Other outcomes
Other investigated outcomes of the included study were cardiovas-
cular risk factors. Low-density lipoprotein (LDL) fell in both treat-
ment groups. The difference between treatment groups was not
significant (0.14 mmol/L; 95% CI -0.44 to +0.17; P = 0.37). High-den-
sity lipoprotein (HDL) were significantly lower with HRT than place-
bo (-0.2; 95% CI -0.28 to -0.11; P < 0.001). Subgroup analysis be-
tween T1DM and T2DM showed a decrease in mean HDL in T1DM
only.
D I S C U S S I O N
Summary of main results
The main finding from the single study (Scott 2004) identified
through our search indicates that hormone replacement therapy
(HRT) may not worsen glycaemic control in women with type 1 di-
abetes. This finding is in agreement with previous studies involv-
ing women who have type 2 diabetes (Crespo 2002; Ferrara 2001).
However, there are limitations in the Scott 2004 study that must be
considered. No pre- or post-intervention information regarding gly-
cosylated haemoglobin A1c (HbA1c) change was provided, which
presents a limitation if the effects of HRT and glycaemic control are
to be understood. In addition, no information regarding insulin reg-
imen was provided, nor was there any information relating to the
amount of exogenous insulin taken. Therefore, it is not clear if the
study participants in Scott 2004 altered their insulin intake through-
out the study.
The complexity surrounding HRT and its affects on many of the
physiological responses in women with diabetes are considerable.
For example, women with type 1 diabetes tend to experience symp-
toms of menopause earlier than women without diabetes, which
can potentially lead to a reduction in reproductive years (Dorman
2001). Furthermore, menstrual irregularities are reported more fre-
quently in women with type 1 diabetes than women without dia-
betes and they particularly appear to have difficulty in controlling
blood glucose levels around the time of menstruation (Strotmeyer
2006). It is perhaps not surprising that as a consequence, due to the
lack of empirical evidence detailing the effects of HRT on glycaemic
control, evidence-based guidelines on how to manage glycaemia
during the menopause for women with type 1 diabetes are unavail-
able.
Thus, information regarding how HRT affects glycaemic control in
women with type 1 diabetes is unclear. Studies which have report-
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ed glycaemic effects are limited (Scott 2004) and are often ham-
pered by small sample sizes (Dorman 2001).
The key finding of this review is that HRT does not appear to wors-
en glycaemic control in women with type 1 diabetes. However, as
previously discussed, findings from that study must be taken with
caution given the study limitations.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is currently a lack of evidence regarding the use of hormone
replacement therapy amongst menopausal women with type 1 di-
abetes. HRT may impact upon glycaemic control and cardiovascu-
lar risk of women with type 1 diabetes but this review cannot make
any recommendations for practice.
Implications for research
Research to examine this topic needs to be undertaken to inform
future practice. Randomised controlled trials to measure the im-
pact of HRT on glycaemic control and cardiovascular risk factors in
women with type 1 diabetes are possible. Descriptive and qualita-
tive studies would be beneficial to examine the impact of HRT from
the healthcare professional and patient perspectives.
A C K N O W L E D G E M E N T S
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Characteristics of included studies [ordered by study ID]
 
Methods Randomised controlled clinical trial
Participants Inclusion criteria: postmenopausal women (amenorrhoeic for at least one year or were aged up to 53
years and been receiving HRT in the past for at least six months)
Exclusion criteria: uncontrolled hypertension (diastolic > 100 mmHg), renal impairment (creatinine
> 150 μmol/L), previous malignancy, unstable angina, myocardial infarction previous six months, hys-
terectomy or a history of excess alcohol consumption or taking warfarin or drugs which may interfere
with oestrogen metabolism
Diagnostic criteria: amenorrhoeic for at least one year or were aged up to 53 years and had been re-
ceiving HRT in the past for at least six months
Co-morbidities: not stated
Co-medications: not stated
Interventions Number of study centres: 11 centres nationwide
Country/location: UK
Setting: delivered by healthcare professionals from hospital diabetic clinics in the UK
Intervention: oestrogen (17B-oestradiol, 2 mg) and progesterone (norethisterone acetate, 1 mg)
Control: placebo (no details stated)
Treatment before study: participants had been receiving HRT in the past for at least six months
Outcomes Outcome(s) (as stated in the protocol/registered trial documents):
Primary outcome(s):
Total cholesterol (cholesterol oxidase fully enzymatic assay)
LDL (polyethylene glycol (PEG) precipitation)
HDL (polyethylene glycol (PEG) precipitation)
Triglycerides (lipase/glycerol 3-phosphate oxidase assay)
Fibrinogen (immunoturbidimetric assay)
Body mass index (kg/m2)
Blood pressure (mm Hg)
Secondary outcomes: not stated
Scott 2004 
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Additional outcomes: not stated
Study details After a 6-week run-in period, the study lasted for 12 months
Publication details This study was commercially funded
Stated aim of study "...was to examine the effects of HRT (Kliofem) on cardiovascular risk factors, including lipid profile, gly-
caemic control, blood pressure and body weight, in postmenopausal women with T1DM or T2DM"
Notes Key findings: this study demonstrates that HRT results exert a minimal effect on glycaemic control. In
relation to cardiovascular risk factors, HRT appears to have a neutral effect on most, though the effects
on HDL warrants further investigation.
Quote from publication: "None of the interactions between type of diabetes (T1DM or T2DM) and treat-
ment (Kliofem/placebo) achieved statistical significance for any of the variables analysed; hence, all re-
sults are reported for the total number of diabetics completing the study"
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Comment: method of concealment is not described.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Comment: no information on blinding method is given.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "Variables missing values for the 52-week visit were replaced using the
last observation carried forward technique ... Where week 0 values were miss-
ing, they were replaced by the week -6 values"
Selective reporting (re-
porting bias)
Low risk Comment: all of the study's outcomes have been reported
Other bias High risk Quote: "55 patients withdrew from the study...main reasons were adverse ef-
fects or persistence of menopausal symptoms"
Comment: no information is provided detailing the differences in drop-out
rate between type 1 diabetes mellitus and type 2 diabetes mellitus
Scott 2004  (Continued)
HDL: high-density lipoprotein; HRT: hormone replacement therapy; LDL: low-density lipoprotein
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Brown 2001 Not type 1 diabetes participants
Hayward 2001 Not type 1 diabetes participants
Kanaya 2003 Not type 1 diabetes participants
 
 
Hormone replacement therapy for women with type 1 diabetes mellitus (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
A D D I T I O N A L   T A B L E S
Hormone replacement therapy for women with type 1 diabetes mellitus (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15
H
orm
one replacem
ent therapy for w
om
en w
ith type 1 diabetes m
ellitus (Review
)
Copyright ©
 2013 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
16
Characteristic
Study ID
Intervention(s) and com-
parator (s)
[N]
screened /
eligible
[N]
randomised
[N]
safety
[N]
ITT
[N]
finishing
study
[%] randomised
participants
finishing study
Scott 2004a Hormone replacement thera-
py vs placebo
I: 27
C: 29
T: 56
I: 27
C: 29
T: 56
- - - N/A
All interventions 27
All controls 29
Total
All interventions and con-
trols
 
56
 
Table 1.   Overview of study populations 
"-" denotes not reported
aData on drop-outs, losses to follow-up and missing data were not reported in the type 1 diabetes mellitus participants
C: comparator; I: intervention; N/A: not applicable
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A P P E N D I C E S
Appendix 1. Search strategies
 
Search terms and databases
Unless otherwise stated, search terms are free text terms.
Abbreviations:
'$': stands for any character; '?': substitutes one or no character; adj: adjacent (i.e. number of words within range of search term); exp:
exploded MeSH; MeSH: medical subject heading (MEDLINE medical index term); pt: publication type; sh: MeSH; tw: text word.
The Cochrane Library
The Cochrane Library 
#1 MeSH descriptor Diabetes mellitus, type 1explode all trees
#2  MeSH descriptor Diabetic Ketoacidosis explode all trees
#3   MeSH descriptor Diabetes Complications explode all trees
#4   (IDDM in All Text or T1DM in All Text)
#5   ((insulin* in All Text and depend* in All Text) or insulin?depend* in All Text)
#6   (typ* in All Text and 1 in All Text and adj6 in All Text and diabet* in All Text)
#7   (earl* in All Text and adj6 in All Text and diabet* in All Text)
#8   (auto?immun* in All Text and adj6 in All Text and diabet* in All Text)
#9   ((sudden in All Text and onset in All Text) and adj6 in All Text and diabet* in All Text)
#10  (insulin* in All Text and defic* in All Text and adj6 in All Text and absolut* in All Text)
#11  (acidos* in All Text and adj6 in All Text and diabet* in All Text)
#12 (juvenil* in All Text and adj6 in All Text and diabet* in All Text)
#13  (child* in All Text and adj6 in All Text and diabet* in All Text)
#14  (keto* in All Text and adj6 in All Text and diabet* in All Text)
#15  (labil* in All Text and adj6 in All Text and diabet* in All Text)
#16  (britt* in All Text and adj6 in All Text and diabet* in All Text)
#17  (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16)
#18  MeSH descriptor Diabetes insipidus explode all trees
#19  (diabet* in All Text and insipidus in All Text)
#20  (#18 or #19)
#21  (#17 and not #20)
#22  MeSH descriptor Hormone replacement therapy explode all trees
#23  (hormon* in All Text and (replacement in All Text AND therap* in All Text) )
#24  (hormon* in All Text and (replacement in All Text AND intervention* in All Text) )
#25  (#22 or #23 or #24)
#26  #21 and #25
MEDLINE
1. exp Diabetes Mellitus, Type 1/
2. exp Diabetic Ketoacidosis/
3. exp Diabetes Complications/
4. (IDDM or T1DM or T1D).tw,ot.
5. (("insulin* depend*" or "insulin?depend*") not ("non-insulin* depend*" or "noninsulindepend*")).tw,ot.
6. (("typ? 1" or "typ? I" or "typ?1" or "typ?I") adj2 diabet*).tw,ot.
7. ((acidos* or juvenil* or child* or keto* or labil* or britt*) adj2 diabet*).tw,ot.
8. ((auto-immun* or autoimmun* or sudden onset) adj2 diabet*).tw,ot.
9. (insulin* defic* adj2 absolut*).tw,ot.
10. or/1-9
11. exp Diabetes Insipidus/
12. diabet* insipidus.tw,ot.
13. 11 or 12
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14. 10 not 13
15. exp Hormone Replacement Therapy/
16. hormone replacement*.tw,ot.
17. or/15-16
18. 14 and 17
19. (animals not (animals and humans)).sh.
20. 17 not 18
21. Limit 20 to RCT
EMBASE
1. exp Insulin Dependent Diabetes Mellitus/
2. exp Diabetic Ketoacidosis/
3. exp Diabetic Retinopathy/ or exp Diabetic Angiopathy/ or exp Diabetic Neuropathy/ or
4. exp Diabetic Nephropathy/
5. (IDDM or T1DM).tw,ot.
6. (insulin$ depend$ or insulin?depend$).tw,ot.
7. ((typ$ 1 or typ$I) adj6 diabet$).tw,ot.
8. ((earl$ or auto?immun$ or sudden onset) adj6 diabet$).tw,ot.
9. (insulin$ defic$ adj6 absolut$).tw,ot.
10. ((acidos$ or juvenil$ or child$ or keto$ or labil$ or britt$) adj6 diabet$).tw,ot
11. or/1-9
12. exp Diabetes Insipidus/
13. diabet$ insipidus.tw,ot.
14. 11 or 12
15. 10 not 13
16. exp hormone substitution/
17. (hormon* adj3 (substitution* or replacement*)).tw,ot.
18. or/15-16
19. 14 and 17
20. limit 18 to human
21. limit 19 to RCT
CINAHL
1. (MH "Diabetes Mellitus, Type 1")
2. (MH "Diabetic Ketoacidosis")
3. Diabetes Complications/
4. (IDDM or T1DM or T1D).tw,ot.
5. (("insulin* depend*" or "insulin?depend*") not ("non-insulin* depend*" or "non insulindepend*")).tw,ot.
6. (("typ? 1" or "typ? I" or "typ?1" or "typ?I") adj2 diabet*).tw,ot.
7. ((acidos* or juvenil* or child* or keto* or labil* or britt*) adj2 diabet*).tw,ot.
8. ((auto-immun* or autoimmun* or sudden onset) adj2 diabet*).tw,ot.
9. (insulin* defic* adj2 absolut*).tw,ot.
10. or/1-9
11. exp Diabetes Insipidus/
12. diabet* insipidus.tw,ot.
13. 11 or 12
14. 10 not 13
15. exp Hormone Replacement Therapy/
16. hormone replacement*.tw,ot.
17. exp Menopause, Premature/ or exp Menopause/
18. (menopaus$ or postmenopaus$ or perimenopaus$ or premenopaus$).tw,ot.
19. or/15-18
20. 14 and 19
21. limit 18 to female
22. (animals not (animals and humans)).sh.
23. 19 not 20
  (Continued)
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PsycINFO
1. (TX+(Diabetes+Mellitus))+OR+(TX+(Type+1)))
2. (TX+(Diabetic+Ketoacidosis))
3. (TX+(Diabetes+Complications))
4. (TX+(IDDM))+OR+(TX+(T1DM))
5. ((TX+(insulin*+AND+depend*))+OR+(TX+(insulin%3fdepend*)))
6. ((TX+(typ*)+AND+1+AND+adj6+AND+diabet*))+OR+((TX+(earl*)+AND+TX+(adj6)+AND+TX+(diabet*)))
7. ((TX+(auto%3fimmun*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
8. ((TX+(sudden+AND+onset))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
9. ((TX+(insulin*))+AND+(TX+(defic*))+AND+(TX+(adj6))+AND+(TX+(absolut*)))
10. ((TX+(acidos*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
11. ((TX+(juvenil*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
12. ((TX+(child*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
13. ((TX+(keto*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
14. ((TX+(labil*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))
15. ((TX+(britt*))+AND+(TX+(adj6))+AND+(TX+(diabet*)))))
16. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15
17. (TX+(diabetes+insipidus)))
18. ((TX+(diabet*))+AND+(TX+(insipidus)))))))
19. S17 OR S18
20. S16 NOT S19
21. ((((MJ+(Hormone+Replacement+Therapy)))
22. ((TX+(hormon*+AND+replacement+AND+therap*)))
23. ((TX+(hormon*+AND+replacement+AND+intervention*))))))
24. S21 OR S22 OR S23
25. S20 AND S24
  (Continued)
 
Appendix 2. Description of interventions
 
Characteristic
Study ID
Intervention [route, frequency, total dose/day] Comparator [route, frequency,
total dose/day]
Scott 2004 Hormone replacement therapy (oestrogen (17B-oestradiol, 2 mg) and
progesterone (norethisterone acetate, 1 mg))
Placebo (not described)
 
 
Appendix 3. Baseline characteristics
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Characteristic
Study ID
Duration of intervention
(duration of follow-up)
Participating
population
Age
[mean years
(SD)]
HbA1c
[mean %
(SD)]
BMI
[mean kg/m2
(SD)]
Ethnic
groups
[%]
Duration of disease
[mean years (SD)]
Scott 2004 12 months (at 12 months) 55 60 (6) - 28.5 (6.1) - -
Footnotes
"-" denotes not reported
BMI: body mass index; HbA1c: glycosylated haemoglobin A1c; SD: standard deviation
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Appendix 4. Matrix of study endpoints
 
Characteris-
tic
Primarya endpoint(s) Secondaryb
endpoint(s)
Otherc end-
point(s)
Scott 2004 Cardiovascular risk factors (lipid profile), glycaemic control (fructosamine), blood
pressure, BMI
- -
Footnotes
a,b,as stated in the publication; cnot stated as primary or secondary endpoint(s) in the publication
BMI: body mass index
 
 
Appendix 5. Adverse events (I)
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Characteristic
Study ID
Deaths
[n]
Adverse
events
[n / %]
Severe/
serious
adverse events
[n / %]
Drop-outs due
to adverse events [n /
%]
Hospitalisa-
tion
[n / %]
Out-patient treat-
ment
[n / %]
Hypoglycaemic
episodes
[n / %]
Scott 2004 - - - - - - -
Footnotes
"-" denotes not reported
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Appendix 6. Adverse events (II)
 
Characteristic
Study ID
Severe hypoglycaemic
episodes
[n / %]
Definition of severe /
serious hypoglycaemia
Nocturnal hypoglycaemic
episodes 
[n / %]
Symp-
toms
[n / %]
Scott 2004 - - - -
Footnotes
"-" denotes not reported
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